Riluzole in the treatment of the negative symptoms of schizophrenia
Phase 2
- Conditions
- schizophrenia.Schizophrenia
- Registration Number
- IRCT201107281556N26
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Inclusion Criteria:1- Age between 18-50, 2- Diagnosis of Schizophrenia based on DSM IV 3- chronic Schizophrenia( the duration of the disorder> 2 years), Minimum Score of 60 on Positive and Negative Scale
Exclusion Criteria
1- Substance dependence,2- IQ <70,3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month,6- receiving ECT during the last 14 days,7- hepatic disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the severity of negative symptoms. Timepoint: Baseline and weeks 2, 4, 6 and 8 after begining of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method Change in other PANSS subscale scores. Timepoint: Weeks: 2, 4, 6 and 8. Method of measurement: Positive and Negative Syndrome Scale (PANSS).